AJP - Renal AJP: Cell Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Renal Physiol (October 22, 2008). doi:10.1152/ajprenal.00622.2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
296/1/F60    most recent
00622.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rashid, G.
Right arrow Articles by Benchetrit, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rashid, G.
Right arrow Articles by Benchetrit, S.
Submitted on December 31, 2007
Accepted on October 14, 2008

Parathyroid hormone decreases endothelial osteoprotegerin secretion: role of protein kinase A and C

Gloria Rashid1, Eleanora Plotkin2, Osnat Klein3, Janice Green2, Jacques Bernheim4*, and Sydney Benchetrit3

1 Renal Physiology laboratory, Department of Nephrology and Hypertension, Meir Medical Center, Kfar-Saba, Israel
2 Renal Physiology Laboratory, Department of Nephrology and Hypertension, Meir Medical Center, Kfar-Saba, Israel
3 Renal Physiology Laboratory, Department of Nephrology and Hypertension, Meir Medical Center, Kfar-Saba, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
4 Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Renal Physiology laboratory, Department of Nephrology and Hypertension, Meir Medical Center, Kfar-Saba, Israel

* To whom correspondence should be addressed. E-mail: nephrol{at}clalit.org.il.

Parathyroid hormone (PTH), which is elevated in patients with chronic renal failure, has been shown to participate in the development of vascular calcification. Previous studies have demonstrated that PTH may promote endothelial expressions of proinflammatory parameters. On the basis of these data, we evaluated whether PTH may have an impact on endothelial osteoprotegerin (OPG), a vascular protective factor which may control vascular calcification. Endothelial cells were stimulated with 10-12-10-10 mol/L PTH. Protein kinase C (PKC) and protein kinase A (PKA) are the main cellular pathways of PTH. Inhibitors and activators of PKC or PKA were used to determine if these signaling pathways are involved in the control of endothelial OPG. PTH induced a decrease in OPG secretion and mRNA expression. Treatment of PTH-stimulated cells by Calphostin C (PKC inhibitor) induced a further decrease in OPG secretion, while Rp-cAMP (PKA inhibitor) had no additional effect. In non-stimulated cells, PKC activator significantly stimulated OPG secretion, while PKA activator was associated with a decline. These effects were blunted in the presence of Calphostin C and Rp-cAMP respectively. An increase in OPG secretion induced by a PKC activator indicates that the basal OPG secretion is mediated through PKC. The decrease induced by a PKA activator, which is similar to that observed with PTH, suggests that, the action of PTH on OPG secretion and mRNA expression may be due to the PKA pathway.




This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
Y. Talmor-Barkan, G. Rashid, I. Weintal, J. Green, J. Bernheim, and S. Benchetrit
Low extracellular Ca2+: a mediator of endothelial inflammation
Nephrol. Dial. Transplant., November 1, 2009; 24(11): 3306 - 3312.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1977 by the American Physiological Society.